arrow_back Back to App

Study on Pharmaceutical Advertising's Impact on Drug Costs for Consumers

This act mandates a study to investigate how direct-to-consumer pharmaceutical advertising affects drug prices for consumers. The goal is to understand if these advertisements increase drug costs paid by citizens and how to address this. The study's findings will be publicly available, helping citizens better understand drug pricing mechanisms.
Key points
Mandates a study on how direct-to-consumer pharmaceutical advertising impacts drug costs.
Examines ways to reduce drug costs by splitting advertising expenses among manufacturers.
Assesses the role of advertisements in promoting potentially unnecessary medications to patients.
Study results will be made public, increasing transparency in the pharmaceutical market.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_4278
Sponsor: Rep. Murphy, Gregory [R-NC-3]
Process start date: 2021-06-30
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

To direct the Comptroller General of the United States to conduct a study on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers, and for other purposes.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_4278.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-06-30.

What are the main provisions?

Key points include:

  • Mandates a study on how direct-to-consumer pharmaceutical advertising impacts drug costs.
  • Examines ways to reduce drug costs by splitting advertising expenses among manufacturers.
  • Assesses the role of advertisements in promoting potentially unnecessary medications to patients.
  • Study results will be made public, increasing transparency in the pharmaceutical market.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Murphy, Gregory [R-NC-3].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health Economy